Search: WFRF:(Ohrfelt Annika) > Evaluation of the C...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03429naa a2200433 4500 | |
001 | oai:lup.lub.lu.se:c496ca1d-0235-41c2-a64c-f9cafb310b55 | |
003 | SwePub | |
008 | 160401s2013 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/42725982 URI |
024 | 7 | a https://doi.org/10.1159/0003534422 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Nutu, Magdalena4 aut |
245 | 1 0 | a Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders |
264 | c 2013-07-09 | |
264 | 1 | b S. Karger AG,c 2013 |
520 | a Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB. (C) 2013 S. Karger AG, Basel | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a Amyloid-beta | |
653 | a Alzheimer's disease | |
653 | a Parkinson's disease | |
653 | a Immunoassays | |
653 | a Amplified luminescent proximity homogenous immunoassay | |
700 | 1 | a Zetterberg, Henrik4 aut |
700 | 1 | a Londos, Elisabetu Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups4 aut0 (Swepub:lu)pski-elo |
700 | 1 | a Minthon, Lennartu Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups4 aut0 (Swepub:lu)psyk-lmi |
700 | 1 | a Nägga, Katarinau Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups4 aut0 (Swepub:lu)med-kng |
700 | 1 | a Blennow, Kaj4 aut |
700 | 1 | a Hansson, Oskaru Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups4 aut0 (Swepub:lu)mphy-ohn |
700 | 1 | a Ohrfelt, Annika4 aut |
710 | 2 | a Klinisk minnesforskningb Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Dementia and Geriatric Cognitive Disordersd : S. Karger AGg 36:1-2, s. 99-110q 36:1-2<99-110x 1420-8008x 1421-9824 |
856 | 4 | u http://dx.doi.org/10.1159/000353442y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/4272598 |
856 | 4 8 | u https://doi.org/10.1159/000353442 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.